Daily Morning Note – 19 November 2020

PHILLIP SUMMARY

Asian stocks look set to come under pressure after U.S. shares closed at their lows as restrictions to curb the coronavirus spread overshadowed progress toward a vaccine. The dollar held near its lowest in two years.

Futures slipped in Japan and Australian shares retreated. S&P 500 futures were little changed with the benchmark closing at its session low after New York City shut schools because of rising infections. Pfizer Inc. advanced after saying its vaccine was 95% effective, paving the way to apply for the first U.S. regulatory authorization for a coronavirus shot within days. The Bloomberg Dollar Spot Index earlier fell to the lowest since April 2018 as vaccine optimism lifted commodity prices and resource-linked currencies. Benchmark Treasury yields ticked higher.

BREAKING NEWS

A troubled Indian bank may be folded into DBS Group’s India business under a proposed scheme by the Reserve Bank of India (RBI), DBS said in a Singapore Exchange filing late on Tuesday night. If the scheme is approved, DBS will inject INR 2,500 crore (S$463 million) into its wholly-owned unit DBS Bank India Ltd (DBIL) to support the amalgamation. This will be fully funded from DBS’s existing resources.

Capitaland Retail China Trust’s (CRCT) preferential offering to unitholders has been priced at S$1.17, the bottom end of the indicative range. That’s at an 8.6 per cent discount to Monday’s closing price of S$1.28, and a discount of about 9.2 per cent to the volume-weighted average price (VWAP) of S$1.2891 for all trades done on Monday. The non-renounceable preferential offering will be done on the basis of 56 new units for every 1,000 existing units held as at the record date of Nov 25, 5pm, said CRCT’s manager in a bourse filing on Wednesday.

Quarz Capital and Black Crane Capital, in a joint statement released on Wednesday and seen by The Business Times, said they intend to requisition an extraordinary general meeting (EGM) for the internalisation of the manager of Shari’ah Compliant Industrial Real Estate Investment Trust (Sabana Reit). The fund managers also said this should be done after the proposed merger of Sabana Reit with ESR-Reit falls through, reiterating their call for Sabana unitholders to vote against it. They noted that with an internal manager, the distribution per unit (DPU) “immediately increases” by some 7.5 per cent through elimination of the management fees paid to ESR Cayman, which has a controlling ownership of Sabana Reit’s manager.

Mainboard-listed dormitory developer and operator Centurion Corp has secured a master lease to manage a new purpose-built dormitory in Selangor, adding more than 5,000 beds to its Malaysian portfolio, it announced on Wednesday night. The lease was secured through Knight Frank Malaysia from the Selangor State Development Corporation. This addition brings the group’s purpose-built workers accommodation portfolio up to eight properties with a total of some 35,700 beds, under its Westlite Accommodation brand.

City Developments Limited (CDL) hotel arm Millennium & Copthorne Hotels (M&C) is reviewing its portfolio and may dispose of some assets under a drive to recover from the effects of the Covid-19 pandemic by as early as 2021, it said in a statement on Wednesday evening. It said: “Having received expressions of interest for various assets globally, M&C is assessing at least three offers.” It noted that some offers are subject to re-zoning and regulatory approval for a change of use from hospitality. “Based on current offers, M&C expects to conclude at least one such sale in 2021.”

Rich Capital Holdings’ indirect subsidiary Oxley Batam has issued a letter of demand against a joint-venture partner, which has denied the allegations in the letter, Catalist-listed Rich Capital said on Wednesday night. Oxley Batam issued a Nov 4 letter of demand against PT Karya Indo Batam (PT KIB), with which it had formed joint venture PT Oxley Karya Indo Batam (PT OKIB).

Oil prices firmed by about 1 per cent on Wednesday on hopes Opec and its allies will delay a planned increase in oil output and after Pfizer said its Covid-19 vaccine was more effective than previously reported. The market was also supported by a smaller-than-expected increase in US crude stockpiles last week.

House Democrats voted to stick with Nancy Pelosi as their leader and nominee for speaker, placing confidence in her to unite a fractious caucus despite surprise losses in this month’s election that have emboldened congressional Republicans.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR

TECHNICAL REPORTS

Sunpower Group Ltd

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Sunpower Group (SGX: 5GD) upside is marked by an incomplete wave 3 of the minor phase. As such, we are positive that Sunpower will be heading beyond $1.00 in the long term. Technical also indicate that the bullish sentiment will continue.

>> Read more Technical reports

RESEARCH REPORTS

SATS Ltd – Government relief and vaccine combo

Recommendation: NEUTRAL (Upgraded); TP S$4.40

Last close: S$¬¬4.10; Analyst Paul Chew

– 1H21 results were below expectations. Revenue fell 54% YoY to S$440mn, only 30% of our FY20e. Excluding government relief, net loss of S$197.1mn was 128% of our FY21e loss estimate.

– Government relief of S$152mn in 1H21 almost equivalent to FY20 PATMI of S$168mn.

– SATS managed to cut certain fixed costs to cope with pandemic fallout. Excluding government relief, staff costs declined an estimated S$167mn YoY or 36%.

– We expect net losses for the next two years. Our last target price was pegged at its GFC average of 1.35x P/BV – too bearish. We raise this to lower band of SATS’ pre-Covid P/BV of 3.3x. Our TP rises to S$4.40 from S$1.95. Upgrade to NEUTRAL from SELL as we believe worst has been priced in. While vaccine progress is a major positive, it remains unclear how quickly vaccines can slow down infection rates and normalise air travel. We expect air traffic to remain muted in FY21.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here

RESEARCH VIDEOS

Webinar Of The Week

Market Outlook: (PSR) StarHub, Banks & REIT Results, Banking Monthly, Credit Commentary, SG Weekly & more

Date: 09 November 2020

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #26 – iX Biopharma Ltd; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com